J&J Medical Connect
IMAAVY™

(nipocalimab-aahu)

J&J Medical Connect

Connect with us

  • Products

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

IMAAVY™ (nipocalimab-aahu)
Medical Information

IMAAVY – Comparison to Other FcRn Blockers in Patients with Warm Autoimmune Hemolytic Anemia

Last Updated: 08/27/2026

SUMMARY

  • The company cannot recommend any practices, procedures, or usage of IMAAVY that deviate from the approved labeling.
  • There are no head-to-head, randomized, controlled clinical trials comparing the safety and efficacy of IMAAVY to other neonatal fragment crystallizable receptor (FcRn) blockers in patients with warm autoimmune hemolytic anemia (wAIHA).

Literature Search

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, and DERWENT® (and/or other resources, including internal/external databases) conducted on 01 July 2026 did not identify any relevant citations pertaining to this topic.

Would you like to clear and leave your conversation? Message history will be lost.